BetaPublic beta

Spending
Lobbying
Coming soon: Congress, Stocks

Spending
Lobbying
Congress
Stocks

About Privacy Terms

© 2026 Adaptrex, LLC

About
Privacy
Terms

© 2026 Adaptrex, LLC

Spending
Lobbying
Coming soon: Congress, Stocks

Overview Firms Clients Revolving Door Stands Out

IMMUNOMIC THERAPEUTICS — Lobbying — Receipts Report

LD-2 disclosure · 2nd Quarter - Report

IMMUNOMIC THERAPEUTICS

via ML STRATEGIES, LLC

2nd Quarter (Apr 1 - June 30) · 2020Posted Jul 20, 2020Filing document ↗LDA record ↗

Income$30Kfee reported

Client

Name: IMMUNOMIC THERAPEUTICS
Description: Biotechnology company
Location: Maryland · United States of America

Registrant

Firm: ML STRATEGIES, LLC
Description: Government relations consulting firm
Location: Washington, District of Columbia, United States of America

Lobbying activities

2 issues

Economics/Economic Development
Issues related to federal funding regarding COVID-19
LobbyistsFRANK GUINTA · AARON JOSEPHSON · mr ALEXANDER NATHAN HECHT
Covered position (FRANK GUINTA): Member of Congress, New Hampshire 1st District
Covered position (mr ALEXANDER NATHAN HECHT): Chief Counsel, Senate Committee on Small Business & Entrepreneurship
TargetedSENATE · HOUSE OF REPRESENTATIVES · Office of the Vice President of the United States
Health Issues
Issues related to federal funding regarding COVID-19
LobbyistsFRANK GUINTA · AARON JOSEPHSON · mr ALEXANDER NATHAN HECHT
Covered position (FRANK GUINTA): Member of Congress, New Hampshire 1st District
Covered position (mr ALEXANDER NATHAN HECHT): Chief Counsel, Senate Committee on Small Business & Entrepreneurship
TargetedSENATE · HOUSE OF REPRESENTATIVES · Office of the Vice President of the United States

Source

Source · Senate Office of Public Records — Lobbying Disclosure Act filings ↗.

Coverage gaps · LD-2 reports a single dollar figure per quarter on ONE basis — income (a fee) or expenses (self-filed spend), never both — so this page never combines them into one "spend" number.